Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Choosing ART for Pediatric Patients

Source: Key Decisions in HIV Care
Listen as Dr Michelle D. Collins-Ogle shares some of the key considerations for choosing ART for pediatric patients, including for HIV-exposed newborns and children and adolescents infected with HIV.
Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS
Released: May 26, 2022

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.

Listen as she gives perspectives on:

  • Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmission
  • DHHS guideline–recommended ART regimens for children
  • The ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescents
  • Data for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescents
  • Key ART and management considerations for adolescents and young adults with HIV

Information on this Educational Activity

Faculty

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS

Assistant Professor of Pediatrics
Division of Pediatric Infectious Diseases
Pediatric and Adolescent HIV
Children’s Hospital at Montefiore
Pediatric Hospital of Albert Einstein
College of Medicine
Bronx, New York

Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert audio: Drs Chloe Orkin and Babafemi Taiwo discuss new HIV data presented at IDWeek and HIV Glasgow 2022

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: December 5, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Dr Neha Pandit discusses barriers and solutions to PrEP uptake in key patient populations in this commentary from Clinical Care Options (CCO)

person default Neha Pandit, PharmD, AAHIVP, BCPS Released: December 2, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings